Skip to main content

Table 3 Adverse outcomes

From: Distant survival for patients undergoing surgery using volatile versus IV anesthesia for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study

  TIVA INHA P Value
N (%) N (%)
Dichotomous Outcomes
 30-day Mortality 4 (2.1) 11 (4.7) 0.106
 MACE 4 (2.1) 11 (4.7) 0.106
 MOD 6 (3.3) 9 (3.9) 0.797
 Blood Transfusion 80 (43.5) 78 (33.5) 0.189
  Median (IQR) Median (IQR)  
Continuous Outcomes
 Blood Loss 400 (245,800) 400 (300,800) 0.301
 Length of Stay (days) 15 (13,20) 16 (13,20) 0.920
  1. IQR Interquartile range, MACE Major adverse cardiac events, MOF Multiple organ failure, RR Risk ratio